Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.

XERSNYSE / NASDAQHealthcareSmall cap

$16.97+$0.35 (+2.1%)

Last close · Data as of Nov 20, 2026

Market cap
$1.1B
P/E
1916.5x
EV / EBITDA
28.6x
Revenue
$291.8M
Net margin
0.2%
ROCE
9.1%

+148.1% over the last year

Xeris Biopharma Holdings, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
+52.5%
3M
+97.3%
6M
+172.4%
1Y
+148.1%
5Y
+647.6%

52-week range

Day change +$0.35 (+2.1%) from $17 to $17 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in XERS, bought on each weekday since 2021.

News & filings

What Xeris Biopharma Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

StrengthRevenue grew 43.7% in fiscal 2025.

Concerns (1)

  • EV / EBITDA of 28.6 against a peer median of 7.3.
  • Shareholders' equity is small against the company's size, so return on equity and debt to equity are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois.

Read moreShow less

Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Sector
Healthcare
Shares outstanding
166.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.1B
P/E
1916.5x
P/B
77.6x
EV / EBITDA
28.6x
EV / Sales
4.1x
P/S
3.6x
52-week high
$16.99
52-week low
$5.29

Profitability

Operating margin
8.5%
Net margin
0.2%
EBITDA margin
14.5%
ROE
4.0%
ROCE
9.1%
ROIC
18.4%
ROA
0.1%
Asset turnover
0.76

Growth

Revenue
$291.8M
Revenue growth, 1Y
43.7%
Revenue CAGR, 3Y
38.3%
Net profit growth, 1Y
-101.0%
Free cash flow
$27.9M

Solvency

Current ratio
2.19
Debt / Equity
18.85
Debt / Assets
0.67
CFO / Net profit
51.67
Cash / Market cap
10.5%

Where the revenue went

Of every $100 of FY2025 revenue, $0 was left as net income.

Xeris Biopharma Holdings, Inc. income statement flow, FY2025
Xeris Biopharma Holdings, Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$42.6M
RevenueGross profit$249.3M
Gross profitResearch and development$31.2M
Gross profitSelling, general and administrative$182.4M
Gross profitOther operating expenses$10.9M
Gross profitOperating income$24.9M
Operating incomePretax income$550.0k
Operating incomeInterest and other expense$24.3M
Pretax incomeNet income$550.0k

Revenue and net profit

Revenue grew 43.7% in FY2025; net profit is the dashed line.

Xeris Biopharma Holdings, Inc. revenue and net profit by fiscal year
Xeris Biopharma Holdings, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$110.2M-$94.7M
FY2023$163.9M-$62.3M
FY2024$203.1M-$54.8M
FY2025$291.8M$554.0k

Cash flows

FY2025: $28.6M from operations, $27.9M free after investment (dashed).

Xeris Biopharma Holdings, Inc. operating and free cash flow by fiscal year
Xeris Biopharma Holdings, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$102.9M-$103.4M
FY2023-$47.0M-$49.3M
FY2024-$37.0M-$37.8M
FY2025$28.6M$27.9M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$291.8M+43.7%1Y
EBITDA
$42.3M
Net profit
$554.0k
Cash from operations
$28.6M
Free cash flow
$27.9M
Revenue CAGR, 3Y
38.3%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$291.8M$42.3M$554.0k$27.9M4.0%+43.7%-101.0%

Monthly returns

Month-by-month returns of XERS across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$383.5M
Liabilities$369.8M
Equity$13.7M
Paid-in capital$685.0M
Retained earnings-$671.3M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; XERS highlighted.

P/E against peers

XERS trades at 1916.5x earnings against a peer median of 8.0x (a 23943% premium).

  1. Xeris Biopharma Holdings, Inc. (this company)1916.5x

Not shown (no positive earnings and no EV / Sales): Savara Inc., Omada Health, Inc., Azenta, Inc., QuidelOrtho Corporation.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Xeris Biopharma Holdings, Inc.XERSthis companyP/E ↑ premium$1.1B1916.5x77.6x4.0%28.6x
MannKind CorporationMNKD$1.1B185.5x-21.3x-11.5%26.8x
Savara Inc.SVRA$1.1B-9.1x5.3x-58.5%-8.8x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
Azenta, Inc.AZTA$1.1B-18.9x0.6x-3.2%20.8x
The Pennant Group, Inc.PNTG$1.0B35.4x3.1x8.9%24.4x
QuidelOrtho CorporationQDEL$1.0B-0.9x0.5x-58.9%-7.7x
Peer median—8.0x2.1x-4.4%7.3x

Year-to-date ROI

XERS since 1 January, against earlier years.

Historical volatility

XERS's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Xeris Biopharma Holdings, Inc. operating margin by fiscal year
Xeris Biopharma Holdings, Inc. operating margin by fiscal year
DateOperating margin
FY2022-74.3%
FY2023-26.9%
FY2024-16.6%
FY20258.5%
LineFY2025
Cost of revenueCost Of Revenue$42.6M
Gross profitGross Profit$249.3M
Operating expensesOperating Expense$224.4M
Research and developmentResearch And Development$31.2M
Selling, general and administrativeSelling General And Administration$182.4M
Depreciation and amortisationDepreciation And Amortization In Income Statement$10.8M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$10.8M
Amortization$10.8M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$10.8M
Total expensesTotal Expenses$266.9M
Pretax incomePretax Income$550.0k

Learn while you research

Academy chapters picked for Xeris Biopharma Holdings, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Valuation Multiples ExplainedThis stock trades at a P/E of 1916.5, learn when high multiples are justified.6 min read
  3. 03 Growth Investing44% revenue growth is in the top tier, learn how to value growth.7 min read
  4. 04 Leverage RatiosDebt/Equity of 18.85 is elevated, understand what that means for solvency.6 min read
  5. 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  6. 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
Browse the full Equiscale Academy →